To increase transparency, India’s patent regulator will soon make public details about patented drugs which include whether domestic demand for these medicines is met at a reasonable price. Patent holders in the country are required to submit once every year the so-called working details which include the quantity and value of a product that is sold, manufacturing base, quantity of production or imports, and a statement on whether public requirement has...
More »SEARCH RESULT
Total Matching Records found : 242
Need to maintain prices, supply of drug-resistant tuberculosis medicines: Médecins Sans Frontières by Aarti Dhar
As a new rapid diagnostic test, endorsed by the WHO, will finally help detect more people with DR-TB DR-TB medicines are very expensive Need to improve access to DR-TB drugs As a new rapid diagnostic test, endorsed by the World Health Organisation (WHO), will finally help detect more people with drug-resistant tuberculosis (DR-TB), there was need to solve problems around the pricing and supply of DR-TB medicines, according to a report by international...
More »MNC pharma firms campaigning against Indian cos: govt
The government today said multi national companies (MNCs) are campaigning against domestic pharma industry as their interests were getting impacted due to increasing global presence of Indian firms in the generic segment. In a written reply to the Lok Sabha, Minister of State for Commerce and Industry Jyotiraditya Scindia said: "A concerted campaign against India pharma industry has been launched by MNCs whose interests are getting adversely impacted due to increasing...
More »Patients rally against trade pact with EU
Patients battling cancer, infections and mental illness joined a rally here today beseeching the government to reject a trade pact with the European Union that they fear will threaten the availability of inexpensive generic medicines in India. An estimated 2,000 people, many among them infected with HIV, walked along Delhi’s Parliament Street on a day when Indian and EU officials were negotiating a free trade agreement in Brussels. Health activists and lawyers...
More »HIV patients say ‘no' to IP provision on generic drugs by Aarti Dhar
‘It will hinder access to quality, affordable generic medicines produced in India' People in Asia living with HIV and who depend on affordable generic AIDS medicines to stay alive have impressed upon the Indian government to stand strong against European Union demands on the sensitive Intellectual Property (IP) chapter in ongoing Free Trade Agreement (FTA) negotiations. The EU is pushing for harmful IP provisions to be included in the trade agreement...
More »
